

15th March 2016

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087 Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG Societe Anonyme 11, av de la Porte-Neuve, L-2227 Luxemberg

Dear Sirs,

This is further to our intimation dated 12th May, 2014 (copy enclosed).

We would like to inform you that Cipla (EU) Limited, UK ("Cipla UK"), a wholly owned subsidiary of the Company, has pursuant to the approval of the board of Cipla UK, made an additional investment of USD 3 million in Chase Pharmaceuticals Corporation Inc., US ("Chase") towards full settlement of its obligation under the agreed arrangement for investment in Chase. Consequently, Cipla UK's total investment in Chase would aggregate to approximately USD 5.12 million for a 16.7% stake on a fully diluted basis.

Thank you,

Yours faithfully, For Cipla Limited

Mital Sanghvi
Company Secretary

Encl: as above



Cipla Ltd.

Registered Office:
Cipla House
Peninsula Business Park
Ganpatrao Kadam Marg
Lower Parel
Mumbai – 400 013
India

12th May, 2014

- (1) BSE Ltd Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001
- (2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG Societe Anonyme 11, av de la Porte-Neuve, L-2227 Luxemberg

Dear Sirs,

This is to inform you that Cipla (EU) Limited, UK, ("Cipla") a wholly owned subsidiary of the Company has signed a definitive agreement to invest USD 1.5 million in Chase Pharmaceuticals Corporation Inc, US ("Chase") to acquire 14.6% stake in Chase on a fully diluted basis. Cipla will make an additional USD 4.5 million investment in Chase upon achievement of certain milestones.

Chase is an early stage drug development company developing novel approaches to improve treatments for Alzheimer's disease.

Thank you,

Yours faithfully, For Cipla Limited

Mital Sanghvi

Company Secretary

Phone : (9122) 24826000 • Fax : (9122) 24826120 • Email : contactus@cipla.com • Website : www.cipla.com Corporate Identity Number : L24239MH1935PLC002380